Renovaro (RENB) Competitors $0.50 +0.03 (+6.33%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RENB vs. CMPS, DSGN, LYEL, SAGE, NATR, ALDX, PRQR, IMMP, RZLT, and VNDAShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include COMPASS Pathways (CMPS), Design Therapeutics (DSGN), Lyell Immunopharma (LYEL), Sage Therapeutics (SAGE), Nature's Sunshine Products (NATR), Aldeyra Therapeutics (ALDX), ProQR Therapeutics (PRQR), Immutep (IMMP), Rezolute (RZLT), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry. Renovaro vs. COMPASS Pathways Design Therapeutics Lyell Immunopharma Sage Therapeutics Nature's Sunshine Products Aldeyra Therapeutics ProQR Therapeutics Immutep Rezolute Vanda Pharmaceuticals COMPASS Pathways (NASDAQ:CMPS) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership. Which has preferable earnings and valuation, CMPS or RENB? COMPASS Pathways is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOMPASS PathwaysN/AN/A-$118.46M-$2.20-2.12RenovaroN/AN/A-$80.65M-$0.96-0.52 Which has more risk and volatility, CMPS or RENB? COMPASS Pathways has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Do analysts recommend CMPS or RENB? COMPASS Pathways presently has a consensus price target of $30.67, suggesting a potential upside of 558.08%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, equities research analysts clearly believe COMPASS Pathways is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor CMPS or RENB? COMPASS Pathways received 60 more outperform votes than Renovaro when rated by MarketBeat users. CompanyUnderperformOutperformCOMPASS PathwaysOutperform Votes6080.00% Underperform Votes1520.00% RenovaroN/AN/A Do institutionals & insiders have more ownership in CMPS or RENB? 46.2% of COMPASS Pathways shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 4.3% of COMPASS Pathways shares are held by insiders. Comparatively, 21.7% of Renovaro shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer CMPS or RENB? In the previous week, COMPASS Pathways had 1 more articles in the media than Renovaro. MarketBeat recorded 3 mentions for COMPASS Pathways and 2 mentions for Renovaro. COMPASS Pathways' average media sentiment score of 0.95 beat Renovaro's score of 0.25 indicating that COMPASS Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment COMPASS Pathways 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Renovaro 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CMPS or RENB more profitable? COMPASS Pathways' return on equity of -63.85% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets COMPASS PathwaysN/A -63.85% -51.97% Renovaro N/A -67.54%-52.89% SummaryCOMPASS Pathways beats Renovaro on 9 of the 14 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$79.96M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-0.525.5697.3414.18Price / SalesN/A348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book0.577.885.805.12Net Income-$80.65M$153.61M$119.07M$225.99M7 Day Performance-13.69%-2.00%-1.83%-1.32%1 Month Performance-14.47%-7.47%-3.64%0.60%1 Year Performance-82.57%31.80%31.62%26.23% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro0.8555 of 5 stars$0.50+6.3%N/A-82.6%$79.96MN/A-0.5212News CoverageGap UpCMPSCOMPASS Pathways2.8433 of 5 stars$4.66-2.1%$30.67+558.1%-23.0%$318.84MN/A-2.12120Short Interest ↓DSGNDesign Therapeutics1.7551 of 5 stars$5.48flat$7.00+27.7%+145.7%$310.28MN/A-6.4540LYELLyell Immunopharma0.5018 of 5 stars$1.03-7.2%$1.00-2.9%-46.9%$309.93M$130,000.000.00270High Trading VolumeSAGESage Therapeutics4.2604 of 5 stars$4.91flat$12.89+162.5%-75.1%$300.36M$86.46M0.00690Analyst ForecastNews CoverageGap DownNATRNature's Sunshine Products2.7901 of 5 stars$16.00+0.2%$19.00+18.8%-7.5%$295.68M$445.32M18.18814Positive NewsALDXAldeyra Therapeutics1.6462 of 5 stars$4.76-3.6%$10.00+110.1%+78.9%$294.18MN/A0.0015Analyst RevisionPRQRProQR Therapeutics2.0484 of 5 stars$3.67+1.9%$7.13+94.1%+143.0%$294.05M$7.05M0.00180IMMPImmutep1.3099 of 5 stars$1.96-3.0%$8.50+333.7%+4.8%$293.82M$5.14M0.002,021RZLTRezolute4.1532 of 5 stars$5.01+1.2%$24.13+381.5%+568.0%$290.28MN/A-3.9440VNDAVanda Pharmaceuticals4.4313 of 5 stars$4.90-0.4%$15.50+216.3%+36.9%$286.88M$192.64M0.00203 Related Companies and Tools Related Companies COMPASS Pathways Alternatives Design Therapeutics Alternatives Lyell Immunopharma Alternatives Sage Therapeutics Alternatives Nature's Sunshine Products Alternatives Aldeyra Therapeutics Alternatives ProQR Therapeutics Alternatives Immutep Alternatives Rezolute Alternatives Vanda Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RENB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
